RecruitingPhase 4NCT06993038
Adenosine vs Diltiazem for Treatment of SVT in the ED
COMparison of Adenosine Versus Diltiazem FOR Supraventricular Tachycardia in the ED (COMFORT-ED) - Pilot Trial
Sponsor
Anne E. Zepeski
Enrollment
20 participants
Start Date
Aug 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria2
- Adult patients (18 years and older)
- Diagnosis of acute, stable SVT in the emergency department
Exclusion Criteria8
- Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting).
- Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome
- History of heart failure with reduce ejection fraction (HFrEF) (LVEF\</= 40%)
- Severe bronchoconstrictive lung disease
- Prior hypersensitivity to study medication
- Previously enrolled in pilot study
- Pregnant
- Incarcerated
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGadenosine
IV adenosine at standard doses for SVT (6 mg, 12 mg)
DRUGdiltiazem
IV diltiazem at standard doses for SVT (0.25 mg/kg)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06993038